Related Experiment Video
Updated: May 11, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Proliferative effects of urogastrone-EGF on the intestinal epithelium
R A Goodlad1, T J Wilson, W Lenton
1Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Abstract:
The effects of B-urogastrone/human epidermal growth factor on intestinal epithelial cell proliferation were studied in rats in which intestinal cell proliferation was reduced to a steady state basal level (by maintaining the rats on total parenteral nutrition). Increasing doses of urogastrone progressively raised the two hour collection of metaphases and intestinal weights. The crypt cell production rate was measured in animals maintained parenterally with or without urogastrone, and in rats fed a standard laboratory ration. Continuous infusion of 15 micrograms per rat per day of recombinant beta urogastrone (a dose which has a minimal effect on gastric acid secretion) significantly increased cell proliferation and intestinal tissue weights throughout the gastrointestinal tract. Intravenous infusion of urogastrone was also effective in restoring cell proliferation when it was infused after the intestine had become hypoproliferative. Urogastrone administered through an intragastric cannula thrice daily had no significant effect on either intestinal weight, crypt cell production rate, or metaphase collection.
Related Concept Videos
Mitogens and the Cell Cycle
Renewal of Intestinal Stem Cells
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Gastritis II: Pathophysiology

